V2ACT Therapeutics™, LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer
- V2ACT Therapeutics™, LLC is a joint venture of Genelux Corporation and TVAX Biomedical, Inc.
- V2ACT is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic immunotherapy) and V-ACT (vaccine-enhanced adoptive cell therapy).
- V2ACT capitalizes on:
- Olvi-Vec as an ideal systemic immunomodulator with its excellent safety profile, favorable immune activation effects on the tumor microenvironment and well-documented anti-cancer effects on a wide range of cancers demonstrated in preclinical and phase 2 clinical studies.

Related Keywords

Ingrid Mezo , Gary Wood , Kim Duffy , Miriam Miller , Thomas Zindrick , Biomedical Inc , Genelux Corporation , Drug Administration , Investigational New Drug , Chief Science Officer , கேரி மரம் , கிம் டஃபி , மிரியம் மில்லர் , உயிர் மருத்துவ இன்க் , தலைமை அறிவியல் அதிகாரி ,